extremely excited to share our new story on the impact of JAK inhibition on responses to immune checkpoint blockade in lung cancer patients! 🧬🧑‍🔬 thread on our main findings 🧵 1/n.

RT @jane__huang: Excited to share my graduate work from the @EJohnWherry lab on the molecular mechanisms locking in the differentiation fat….

RT @NancyZh60672287: What gets erased when you integrate single cell data, and can you recover it? Finally, we know what happens and how to….

RT @s_apostolidis: We are currently looking for a motivated Research Specialist to join the Apostolidis Lab! If you're passionate about und….

RT @s_apostolidis: 🚀Very excited to announce that the Apostolidis Lab will open up its doors on July 1st @PennMedicine! We will be focusing….

RT @parkerici: New research from @PennMedicine in @ScienceMagazine, led by PICI Investigators, shows promising results for advanced #NSCLC….

RT @andyjminn: Summary of our paper on combining JAK inhibitors with anti-PD1 for lung cancer (NSCLC). Part of a be….

RT @ScienceMagazine: In two separate Science studies, researchers report that combining JAK inhibitors with checkpoint inhibitor immunother….

10/10 Big thanks to @facts___matter @MaxKlapholz. @NancyZh60672287 @Darwin_ye1 and all the coauthors instrumental in this effort, to the families and patients who participated in our study,and the support provided by @parkerici @UPenn_I3H @PennCancer @themarkfdn.

9/n This study is a testament to the team science done at @PennMedicine with the translational work done in the amazing labs of @andyjminn @EJohnWherry. and the clinical effort led by @MMarmarelis @CoreyLangerMD @Jbauml.

8/n A similar concept was also shown in Hodgkins Lymphoma in the accompanying study by our amazing colleagues at @scrippsresearch @Teijaro_Lab. @zakjerry1 .

7/n We also identify contributing factors as to why the NR patients may not have responded to therapy. Overall our study shows that JAK inhibition during immunotherapy is safe, tolerable, and can lead to improved anti-cancer immunity, illuminating new avenues for treatment!

6/n In fact, by the late blocking of inflammation, we delay the terminal differentiation of responding CD8 T cell clones, increasing their differentiation plasticity in the JAKi.R patients.

5/n These JAKi.R patients show an increase in a progenitor like CD8 T cells during the JAKi treatment window, similar to what has been shown when blocking IFNAR1 in chronic viral infections!

4/n In a phase 2 trial, we observe a subset of patients responding to anti-PD1 early (aPD1.R) and a subset that are unresponsive (NR) . Interestingly, we also observe a third subset that respond after patients are given a JAK inhibitor with anti-PD1 (JAKi.R)

3/n In preclinical models, delayed inhibition of JAK1 can enhance tumor responsiveness to immunotherapy. Blocking of the interferon receptor can phenocopy this effect!

2/n We set out to ask the question: Can chronic interferon be therapeutically targeted during immunotherapy?.

RT @simpak: and also excited today to see @divijmathew paper from the lab online now in @ScienceMagazine , a mammoth effort exploring how J….

RT @CharuAggarwalMD: Scenes from @sitcancer Annual Conference in San Diego. Excellent science, and thrilled to chair the Oral Abstract Se….

RT @facts___matter: Our review is out in @ImmunityCP reviewing CD8 T cells in the Cancer-Immunity Cycle! A wonderful anniversary issue with….